Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4697 | recombinant human interferon Alpha-1b Wiki | 0.58 |
| drug4785 | thymosin alpha 1 Wiki | 0.58 |
| drug1781 | Hydroxychloroquine + azithromycin Wiki | 0.41 |
Navigate: Correlations HPO
There are 3 clinical trials
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.
Description: Change from Baseline to Day 11 in SARS-CoV-2 Viral Load
Measure: Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Time: Baseline, Day 11Description: Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold
Measure: Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold Time: Day 7Description: Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization
Measure: Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization Time: Baseline, Day 11Description: Percentage of Participants Demonstrating Symptom Resolution
Measure: Percentage of Participants Demonstrating Symptom Resolution Time: Day 11Description: Percentage of Participants Demonstrating Symptom Improvement
Measure: Percentage of Participants Demonstrating Symptom Improvement Time: Day 11Description: PK: Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479
Measure: Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479 Time: Day 29Description: PK: Mean Concentration of LY3832479 in the Presence of LY3819253
Measure: PK: Mean Concentration of LY3832479 in the Presence of LY3819253 Time: Day 29Description: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related ER Visit, or Death
Measure: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death Time: Baseline through Day 85Description: Change from Baseline to Day 7 in SARS-CoV-2 Viral Load
Measure: Change from Baseline to Day 7 in SARS-CoV-2 Viral Load Time: Baseline, Day 7Description: Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization, COVID-Related ER Visit, or Death
Measure: Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization, COVID-Related ER Visit, or Death Time: Baseline through Day 29The main purpose of this study is to learn more about the safety of LY3832479 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3832479 is in the bloodstream and how long it takes the body to eliminate it. Participation could last up to 16 weeks and may include up to 10 visits to the study center.
Description: A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Measure: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Time: Baseline through Follow-up (Week 12)Description: PK: AUC of LY3832479
Measure: 2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3832479 Time: Day 1: Pre-dose through Day 85Description: PK: Cmax of LY3832479
Measure: PK: Maximum Concentration (Cmax) of LY3832479 Time: Day 1: Pre-dose through Day 85The purpose of this study is to test the safety and tolerability of LY3832479 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3832479 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.
Description: PK: AUC(0-inf)
Measure: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time 0 to Infinity (AUC[0-inf]) of LY3832479 Time: Day 1 through Day 85Description: PK: Cmax of LY3832479
Measure: PK: Maximum Concentration (Cmax) of LY3832479 Time: Day 1 through Day 85Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports